MarketWatch

National reimbursement negotiations for Carvykti(R) terminated without agreement, devastating Canadians with myeloma

The MarketWatch News Department was not involved in the creation of this content. "Carvykti(R) literally has the potential to save my life, yet this chance is denied to me because I live in Canada." - ...
Nasdaq

Telo Genomics to Present Groundbreaking Individual-Cell Risk Assessment MRD Technology at the Myeloma Canada MRD Implementation Summit 2025

Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ("Telo" or the "Company"), a leader in diagnostic and prognostic innovation through its ...
MarketWatch

CDA recommends public reimbursement of Blenrep(R): A step forward for Canadians living with myeloma

The MarketWatch News Department was not involved in the creation of this content. MONTREAL, Nov. 13, 2025 /CNW/ - Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations ...
Morningstar

The International Myeloma Foundation Thanks Mr. Yelak Biru for His Dedicated Service to the Organization

STUDIO CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) announced today that Mr. Yelak Biru has decided to step down as President & CEO. Mr. Biru’s last day ...